| Schedule of selected quarterly financial data |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, 2018
|
|
Year Ended December 31, 2017
|
|
|
|
|
Q1
|
|
Q2
|
|
Q3
|
|
Q4
|
|
Q1
|
|
Q2
|
|
Q3
|
|
Q4
|
|
|
|
|
(unaudited, in thousands, except per share amounts)
|
|
|
Revenue
|
|
$
|
—
|
|
$
|
1,787
|
|
$
|
4,865
|
|
$
|
37,857
|
|
$
|
3,584
|
|
$
|
—
|
|
$
|
900
|
|
$
|
—
|
|
|
Gross profit*
|
|
$
|
—
|
|
$
|
1,757
|
|
$
|
4,796
|
|
$
|
7,107
|
|
$
|
—
|
|
$
|
—
|
|
$
|
—
|
|
$
|
—
|
|
|
Net loss
|
|
$
|
(24,385)
|
|
$
|
(25,557)
|
|
$
|
(23,766)
|
|
$
|
3,228
|
|
$
|
(15,314)
|
|
$
|
(19,147)
|
|
$
|
(17,660)
|
|
$
|
(25,871)
|
|
|
Net income (loss) per share, basic and diluted:
|
|
$
|
(0.17)
|
|
$
|
(0.16)
|
|
$
|
(0.14)
|
|
$
|
0.02
|
|
$
|
(0.13)
|
|
$
|
(0.16)
|
|
$
|
(0.14)
|
|
$
|
(0.18)
|
|
|
Weighted average shares used in computing net income (loss) per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
147,114
|
|
|
161,577
|
|
|
166,464
|
|
|
166,680
|
|
|
113,598
|
|
|
122,500
|
|
|
124,628
|
|
|
144,252
|
|
|
Diluted
|
|
|
147,114
|
|
|
161,577
|
|
|
166,464
|
|
|
167,617
|
|
|
113,598
|
|
|
122,500
|
|
|
124,628
|
|
|
144,252
|
|
*Gross profit is computed as Net product sales less Cost of product sales. Prior to the FDA approval, manufacturing and related costs were charged to research and development expense. Therefore, these costs were not capitalized and as a result, are not fully reflected in the costs of sales during the periods disclosed above.
|